By Dhirendra Tripathi
The patients who got the drug, rather than endocrine treatment, didn’t live longer without the disease progressing, according to Sanofi.
Oral pill amcenestrant was one of six “potentially transformative” products Sanofi has touted and prioritized and was seen as the French drugmaker’s next blockbuster.
Hopes were also high from the drug, given most of the alternatives in the market are painful shots.
The disappointing result doesn’t mean it’s the end of the road for amcenestrant, but it increases the risk of failure for the other trials, according to analysts at Bloomberg Intelligence.
In the Phase II trial, the patients had advanced disease and few treatment options remaining, and the medicine wasn’t combined with another as is often the case in cancer. The company said it would press ahead with other trials.
Other trials of the drug include one called AMEERA-5, an advanced study in which it’s combined with Pfizer’s IBRANCE as a first line treatment of breast cancer that has spread.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.